Acute Coronary Syndrome in Patients with Atrial Fibrillation: Which is the Benefit/Risk Profile of Triple Antithrombotic Therapy?
Dual antiplatelet therapy is the recommended treatment for all patients with an acute coronary syndrome treated or not with an invasive procedure1-4. Several trials testing clopidogrel5-7 or new antiplatelet agents8,9 clearly showed that the addition of a thyenopiridine to aspirin is associated with a significant improvement of patients' outcomes. Further, even in the case of elective percutaneous coronary procedures, the use of dual antiplatelet therapy is recommended for a medium-long period of time after the procedure2,4,10. (SELECT FULL TEXT TO CONTINUE)
- Received July 27, 2012.
- Accepted July 31, 2012.
- Copyright © 2012, American Heart Association, Inc. All rights reserved. Unauthorized use prohibited